GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
88.20
+2.55 (2.98%)
Nov 21, 2025, 9:54 AM EST - Market open
Company Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAIL, Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,000 |
| CEO | Robert Ragusa |
Contact Details
Address: 1525 O’Brien Drive Menlo Park, California 94025 United States | |
| Phone | 833 694 2553 |
| Website | grail.com |
Stock Details
| Ticker Symbol | GRAL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001699031 |
| CUSIP Number | 384747101 |
| ISIN Number | US3847471014 |
| Employer ID | 86-3673636 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Robert P. Ragusa | Chief Executive Officer and Director |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President |
| Aaron Freidin | Chief Financial Officer |
| Paul Ciccolella | Senior Vice President of Global Development and Operations |
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | Chief Scientific Officer and President International |
| Abram Barth J.D., M.P.H. | General Counsel |
| Alison Highlander | Senior Vice President of Human Resources and Head of People Team |
| Dr. Satnam Alag Ph.D. | Senior Vice President of Software Engineering and Chief Security Officer |
| Andrew John Partridge | Chief Commercial Officer |
| Dr. Eric T. Fung M.D., Ph.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | 144 | Filing |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 424B5 | Filing |
| Nov 13, 2025 | 424B7 | Filing |
| Nov 13, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | SCHEDULE 13G | Filing |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 7, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 20, 2025 | 8-K | Current Report |